{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T20:05:18Z","timestamp":1772136318541,"version":"3.50.1"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-18211-7","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T13:46:03Z","timestamp":1758807963000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Identification of genes related to the effects of bicalutamide and zoladex on benign prostatic hyperplasia"],"prefix":"10.1038","volume":"15","author":[{"given":"Guohui","family":"Peng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zicun","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiuming","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"issue":"5","key":"18211_CR1","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1159\/000496289","volume":"65","author":"S Madersbacher","year":"2019","unstructured":"Madersbacher, S., Sampson, N. & Culig, Z. Pathophysiology of benign prostatic hyperplasia and benign prostatic enlargement: a Mini-Review. Gerontology 65 (5), 458\u2013464. https:\/\/doi.org\/10.1159\/000496289 (2019).","journal-title":"Gerontology"},{"issue":"49","key":"18211_CR2","doi-asserted-by":"publisher","first-page":"843","DOI":"10.3238\/arztebl.2020.0843","volume":"117","author":"A Miernik","year":"2020","unstructured":"Miernik, A. & Gratzke, C. Current treatment for benign prostatic hyperplasia. Dtsch. Arztebl Int. 117 (49), 843\u2013854. https:\/\/doi.org\/10.3238\/arztebl.2020.0843 (2020).","journal-title":"Dtsch. Arztebl Int."},{"issue":"2","key":"18211_CR3","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.pop.2019.02.003","volume":"46","author":"RC Langan","year":"2019","unstructured":"Langan, R. C. Benign prostatic hyperplasia. Prim. Care. 46 (2), 223\u2013232. https:\/\/doi.org\/10.1016\/j.pop.2019.02.003 (2019).","journal-title":"Prim. Care"},{"key":"18211_CR4","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1146\/annurev-med-063014-123902","volume":"67","author":"EH Kim","year":"2016","unstructured":"Kim, E. H., Larson, J. A. & Andriole, G. L. Management of benign prostatic hyperplasia. Annu. Rev. Med. 67, 137\u2013151. https:\/\/doi.org\/10.1146\/annurev-med-063014-123902 (2016).","journal-title":"Annu. Rev. Med."},{"key":"18211_CR5","doi-asserted-by":"publisher","unstructured":"Miernik, A. & Gratzke, C. Current treatment for benign prostatic hyperplasia. Dtsch Arztebl Int. 118, 6. https:\/\/doi.org\/10.3238\/arztebl.m  (2021).","DOI":"10.3238\/arztebl.m"},{"key":"18211_CR6","doi-asserted-by":"crossref","unstructured":"Culig, Z., Madersbacher, S. & Sampson, N. Pathophysiology of benign prostatic hyperplasia and benign prostatic enlargement: a mini-review. Gerontology 65, 5 (2019).","DOI":"10.1159\/000496289"},{"issue":"6","key":"18211_CR7","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1111\/bju.15286","volume":"127","author":"BM Launer","year":"2021","unstructured":"Launer, B. M., McVary, K. T., Ricke, W. A. & Lloyd, G. L. The rising worldwide impact of benign prostatic hyperplasia. BJU Int. 127 (6), 722\u2013728. https:\/\/doi.org\/10.1111\/bju.15286 (2021).","journal-title":"BJU Int."},{"issue":"3","key":"18211_CR8","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1055\/s-0036-1586142","volume":"33","author":"MR Macey","year":"2016","unstructured":"Macey, M. R. & Raynor, M. C. Medical and surgical treatment modalities for lower urinary tract symptoms in the male patient secondary to benign prostatic hyperplasia: a review. Semin Intervent Radiol. 33 (3), 217\u2013223. https:\/\/doi.org\/10.1055\/s-0036-1586142 (2016).","journal-title":"Semin Intervent Radiol."},{"key":"18211_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.urology.2017.11.049","volume":"117","author":"JP Zambon","year":"2018","unstructured":"Zambon, J. P., Koslov, D. S., Mihai, B. & Badlani, G. H. Bladder and ureteral dysfunction leading to hydronephrosis and hydroureteronephrosis in adults. Urology 117, 1\u20138. https:\/\/doi.org\/10.1016\/j.urology.2017.11.049 (2018).","journal-title":"Urology"},{"issue":"9","key":"18211_CR10","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s11934-017-0721-8","volume":"18","author":"F Presicce","year":"2017","unstructured":"Presicce, F., De Nunzio, C. & Tubaro, A. Can Long-term LUTS\/BPH Pharmacological treatment alter the outcomes of surgical intervention?? Curr. Urol. Rep. 18 (9), 72. https:\/\/doi.org\/10.1007\/s11934-017-0721-8 (2017).","journal-title":"Curr. Urol. Rep."},{"issue":"6","key":"18211_CR11","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1007\/s11255-023-03912-7","volume":"56","author":"T Osman","year":"2024","unstructured":"Osman, T. et al. Evaluation of Tamsulosin 0.4\u00a0mg versus 0.8\u00a0mg in management of lower urinary tract symptoms due to benign prostatic enlargement. Int. Urol. Nephrol. 56 (6), 1811\u20131816. https:\/\/doi.org\/10.1007\/s11255-023-03912-7 (2024).","journal-title":"Int. Urol. Nephrol."},{"issue":"7","key":"18211_CR12","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1002\/pros.23780","volume":"79","author":"Q Yu","year":"2019","unstructured":"Yu, Q. et al. New strategies for Inhibition of non-adrenergic prostate smooth muscle contraction by Pharmacologic intervention. Prostate 79 (7), 746\u2013756. https:\/\/doi.org\/10.1002\/pros.23780 (2019).","journal-title":"Prostate"},{"key":"18211_CR13","doi-asserted-by":"crossref","unstructured":"Halawani, A. et al. Risks and side effects in the medical management of benign prostatic hyperplasia. Prostate Int. ;12, 1 (2024).","DOI":"10.1016\/j.prnil.2023.11.004"},{"key":"18211_CR14","doi-asserted-by":"crossref","unstructured":"Gandhi, J. et al. The impact and management of sexual dysfunction secondary to Pharmacological therapy of benign prostatic hyperplasia. Transl Androl. Urol. 6, 4 (2017).","DOI":"10.21037\/tau.2017.03.57"},{"key":"18211_CR15","doi-asserted-by":"crossref","unstructured":"Dykes, T. A. et al. Epidemiology and treatment modalities for the management of benign prostatic hyperplasia. Transl. Androl. Urol. 8, 5 (2019).","DOI":"10.21037\/tau.2019.10.01"},{"issue":"9","key":"18211_CR16","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1111\/iju.15518","volume":"31","author":"S Inamura","year":"2024","unstructured":"Inamura, S. & Terada, N. Chronic inflammation in benign prostatic hyperplasia: pathophysiology and treatment options. Int. J. Urol. 31 (9), 968\u2013974. https:\/\/doi.org\/10.1111\/iju.15518 (2024).","journal-title":"Int. J. Urol."},{"issue":"10","key":"18211_CR17","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/S1470-2045(22)00507-1","volume":"23","author":"W Gu","year":"2022","unstructured":"Gu, W. et al. Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial. Lancet Oncol. 23 (10), 1249\u20131260. https:\/\/doi.org\/10.1016\/S1470-2045(22)00507-1 (2022).","journal-title":"Lancet Oncol."},{"issue":"3","key":"18211_CR18","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/sj.pcan.4500504","volume":"4","author":"LM Eri","year":"2001","unstructured":"Eri, L. M. & Tveter, K. J. Effects of bicalutamide and leuprolide on prostate-specific antigen (PSA), acid phosphatase (ACP) and prostatic acid phosphatase (PAP) in men with benign prostatic hyperplasia (BPH). Prostate Cancer Prostatic Dis. 4 (3), 173\u2013177. https:\/\/doi.org\/10.1038\/sj.pcan.4500504 (2001).","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"1","key":"18211_CR19","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.aju.2015.09.007","volume":"14","author":"M Abo El-Enen","year":"2016","unstructured":"Abo El-Enen, M. et al. Goserelin acetate before transurethral resection of moderately enlarged benign prostatic hyperplasia: prospective randomised-controlled clinical trial. Arab. J. Urol. 14 (1), 59\u201365. https:\/\/doi.org\/10.1016\/j.aju.2015.09.007 (2016).","journal-title":"Arab. J. Urol."},{"issue":"6","key":"18211_CR20","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s11154-022-09730-z","volume":"23","author":"K Wel\u00e9n","year":"2022","unstructured":"Wel\u00e9n, K. & Damber, J. E. Androgens, aging, and prostate health. Rev. Endocr. Metab. Disord. 23 (6), 1221\u20131231. https:\/\/doi.org\/10.1007\/s11154-022-09730-z (2022).","journal-title":"Rev. Endocr. Metab. Disord"},{"key":"18211_CR21","doi-asserted-by":"publisher","unstructured":"Kim, M., Tran, P., Yin, J., Song, J. & Kim, H. Cinnamomum cassia and Rosa laevigata mixture improves benign prostatic hyperplasia in rats by regulating androgen receptor signaling and apoptosis. Nutrients 15 (4), 818. https:\/\/doi.org\/10.3390\/nu15040818   (2023).","DOI":"10.3390\/nu15040818"},{"issue":"4\u20135","key":"18211_CR22","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.diff.2011.04.006","volume":"82","author":"TM Nicholson","year":"2011","unstructured":"Nicholson, T. M. & Ricke, W. A. Androgens and estrogens in benign prostatic hyperplasia: past, present and future. Differentiation 82 (4\u20135), 184\u2013199. https:\/\/doi.org\/10.1016\/j.diff.2011.04.006 (2011).","journal-title":"Differentiation"},{"issue":"2","key":"18211_CR23","first-page":"87","volume":"52","author":"L Caprino","year":"2000","unstructured":"Caprino, L. Farmaci per Il Trattamento dell\u2019ipertrofia prostatica Benigna [Drugs for the treatment of benign prostatic hypertrophy]. Minerva Urol. Nefrol. 52 (2), 87\u201392 (2000).","journal-title":"Minerva Urol. Nefrol"},{"key":"18211_CR24","unstructured":"Shah, A. et al. Mechanistic targets for BPH and prostate cancer\u2014a review. Rev. Environ. Health ;35, 3  (2020)."},{"issue":"2","key":"18211_CR25","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.tips.2021.11.004","volume":"43","author":"C Nogales","year":"2022","unstructured":"Nogales, C. et al. Network pharmacology: curing causal mechanisms instead of treating symptoms. Trends Pharmacol. Sci. 43 (2), 136\u2013150. https:\/\/doi.org\/10.1016\/j.tips.2021.11.004 (2022).","journal-title":"Trends Pharmacol. Sci."},{"issue":"1","key":"18211_CR26","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1038\/s41467-020-15913-6","volume":"11","author":"D Liu","year":"2020","unstructured":"Liu, D. et al. Integrative multiplatform molecular profiling of benign prostatic hyperplasia identifies distinct subtypes. Nat. Commun. 11 (1), 1987. https:\/\/doi.org\/10.1038\/s41467-020-15913-6 (2020).","journal-title":"Nat. Commun."},{"issue":"7","key":"18211_CR27","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie, M. E. et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43 (7), e47. https:\/\/doi.org\/10.1093\/nar\/gkv007 (2015).","journal-title":"Nucleic Acids Res."},{"issue":"15","key":"18211_CR28","doi-asserted-by":"publisher","first-page":"3844","DOI":"10.1093\/bioinformatics\/btac409","volume":"38","author":"EK Gustavsson","year":"2022","unstructured":"Gustavsson, E. K. et al. Ggtranscript: an R package for the visualization and interpretation of transcript isoforms using ggplot2. Bioinformatics 38 (15), 3844\u20133846. https:\/\/doi.org\/10.1093\/bioinformatics\/btac409 (2022).","journal-title":"Bioinformatics"},{"issue":"3","key":"18211_CR29","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1002\/imt2.43","volume":"1","author":"Z Gu","year":"2022","unstructured":"Gu, Z. Complex heatmap visualization. iMeta 1 (3), e43. https:\/\/doi.org\/10.1002\/imt2.43 (2022).","journal-title":"iMeta"},{"key":"18211_CR30","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/1471-2105-12-35","volume":"12","author":"H Chen","year":"2011","unstructured":"Chen, H. & Boutros, P. C. VennDiagram: a package for the generation of highly-customizable Venn and Euler diagrams in R. BMC Bioinform. 12, 35. https:\/\/doi.org\/10.1186\/1471-2105-12-35 (2011).","journal-title":"BMC Bioinform."},{"issue":"5","key":"18211_CR31","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu, G. et al. ClusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 16 (5), 284\u2013287. https:\/\/doi.org\/10.1089\/omi.2011.0118 (2012).","journal-title":"OMICS"},{"issue":"11","key":"18211_CR32","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1101\/gr.1239303","volume":"13","author":"P Shannon","year":"2003","unstructured":"Shannon, P. et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13 (11), 2498\u20132504. https:\/\/doi.org\/10.1101\/gr.1239303 (2003).","journal-title":"Genome Res."},{"issue":"24","key":"18211_CR33","doi-asserted-by":"publisher","first-page":"4810","DOI":"10.1093\/bioinformatics\/btab501","volume":"37","author":"M Mahmoudian","year":"2021","unstructured":"Mahmoudian, M. et al. Stable iterative variable selection. Bioinformatics 37 (24), 4810\u20134817. https:\/\/doi.org\/10.1093\/bioinformatics\/btab501 (2021).","journal-title":"Bioinformatics"},{"key":"18211_CR34","doi-asserted-by":"publisher","first-page":"1162458","DOI":"10.3389\/fimmu.2023.1162458","volume":"14","author":"Y Wang","year":"2023","unstructured":"Wang, Y. et al. Unveiling the key genes, environmental toxins, and drug exposures in modulating the severity of ulcerative colitis: a comprehensive analysis. Front. Immunol. 14, 1162458. https:\/\/doi.org\/10.3389\/fimmu.2023.1162458 (2023).","journal-title":"Front. Immunol."},{"issue":"1","key":"18211_CR35","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3390\/ani12010060","volume":"12","author":"LE Robles-Jimenez","year":"2021","unstructured":"Robles-Jimenez, L. E. et al. Worldwide traceability of antibiotic residues from livestock in wastewater and soil: a systematic review. Anim. (Basel). 12 (1), 60. https:\/\/doi.org\/10.3390\/ani12010060 (2021).","journal-title":"Anim. (Basel)"},{"key":"18211_CR36","doi-asserted-by":"publisher","first-page":"989286","DOI":"10.3389\/fimmu.2022.989286","volume":"13","author":"L Wang","year":"2022","unstructured":"Wang, L. et al. Cuproptosis related genes associated with Jab1 shapes tumor microenvironment and Pharmacological profile in nasopharyngeal carcinoma. Front. Immunol. 13, 989286. https:\/\/doi.org\/10.3389\/fimmu.2022.989286 (2022).","journal-title":"Front. Immunol."},{"issue":"7","key":"18211_CR37","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1093\/bioinformatics\/btq064","volume":"26","author":"G Yu","year":"2010","unstructured":"Yu, G. et al. GOSemSim: an R package for measuring semantic similarity among GO terms and gene products. Bioinformatics 26 (7), 976\u2013978. https:\/\/doi.org\/10.1093\/bioinformatics\/btq064 (2010).","journal-title":"Bioinformatics"},{"issue":"5","key":"18211_CR38","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1093\/bib\/bbz106","volume":"21","author":"Y Shen","year":"2020","unstructured":"Shen, Y. et al. Critical evaluation of web-based prediction tools for human protein subcellular localization. Brief. Bioinform. 21 (5), 1628\u20131640. https:\/\/doi.org\/10.1093\/bib\/bbz106 (2020).","journal-title":"Brief. Bioinform"},{"key":"18211_CR39","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1186\/1471-2105-14-244","volume":"14","author":"H Zhang","year":"2013","unstructured":"Zhang, H., Meltzer, P. & Davis, S. RCircos: an R package for circos 2D track plots. BMC Bioinform. 14, 244. https:\/\/doi.org\/10.1186\/1471-2105-14-244 (2013).","journal-title":"BMC Bioinform."},{"key":"18211_CR40","doi-asserted-by":"publisher","first-page":"642000","DOI":"10.3389\/fendo.2021.642000","volume":"12","author":"Y Hu","year":"2021","unstructured":"Hu, Y. et al. Combination usage of adipocount and Image-Pro plus\/imagej software for quantification of adipocyte sizes. Front. Endocrinol. (Lausanne). 12, 642000. https:\/\/doi.org\/10.3389\/fendo.2021.642000 (2021).","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"2","key":"18211_CR41","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s40617-021-00664-7","volume":"15","author":"DR Mitteer","year":"2022","unstructured":"Mitteer, D. R. & Greer, B. D. Using GraphPad prism\u2019s heat maps for efficient, fine-grained analyses of single-case data. Behav. Anal. Pract. 15 (2), 505\u2013514. https:\/\/doi.org\/10.1007\/s40617-021-00664-7 (2022).","journal-title":"Behav. Anal. Pract."},{"issue":"1","key":"18211_CR42","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13578-020-00517-w","volume":"11","author":"Y Zhao","year":"2021","unstructured":"Zhao, Y. et al. Identification of predictors based on drug targets highlights accurate treatment of Goserelin in breast and prostate cancer. Cell. Biosci. 11 (1), 5. https:\/\/doi.org\/10.1186\/s13578-020-00517-w (2021).","journal-title":"Cell. Biosci."},{"issue":"9","key":"18211_CR43","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1111\/jch.14556","volume":"24","author":"H Li","year":"2022","unstructured":"Li, H. et al. Role of \u03b11-blockers in the current management of hypertension. J. Clin. Hypertens. (Greenwich). 24 (9), 1180\u20131186 (2022).","journal-title":"J. Clin. Hypertens. (Greenwich)"},{"key":"18211_CR44","doi-asserted-by":"crossref","unstructured":"Gadzhieva, Z. K. & Kazilov, Y. B. Urologiia 1, 91\u201398 (2016).","DOI":"10.18565\/urol.2017.1.95-102"},{"issue":"4","key":"18211_CR45","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1111\/andr.12353","volume":"5","author":"G Corona","year":"2017","unstructured":"Corona, G. et al. Sexual dysfunction in subjects treated with inhibitors of 5\u03b1-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis. Andrology 5 (4), 671\u2013678. https:\/\/doi.org\/10.1111\/andr.12353 (2017).","journal-title":"Andrology"},{"issue":"1","key":"18211_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13510002.2021.1871814","volume":"26","author":"N Jahan","year":"2021","unstructured":"Jahan, N. et al. Neferine improves oxidative stress and apoptosis in benign prostate hyperplasia via Nrf2-ARE pathway. Redox Rep. 26 (1), 1\u20139. https:\/\/doi.org\/10.1080\/13510002.2021.1871814 (2021).","journal-title":"Redox Rep."},{"key":"18211_CR47","doi-asserted-by":"publisher","first-page":"101950","DOI":"10.1016\/j.redox.2021.101950","volume":"41","author":"D Ross","year":"2021","unstructured":"Ross, D. & Siegel, D. The diverse functionality of NQO1 and its roles in redox control. Redox Biol. 41, 101950. https:\/\/doi.org\/10.1016\/j.redox.2021.101950 (2021).","journal-title":"Redox Biol."},{"issue":"15","key":"18211_CR48","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.3390\/cells13151272","volume":"13","author":"AEMA Khan","year":"2024","unstructured":"Khan, A. E. M. A., Arutla, V. & Srivenugopal, K. S. Human NQO1 as a selective target for anticancer therapeutics and tumor imaging. Cells 13 (15), 1272. https:\/\/doi.org\/10.3390\/cells13151272 (2024).","journal-title":"Cells"},{"key":"18211_CR49","doi-asserted-by":"publisher","first-page":"709829","DOI":"10.3389\/fonc.2021.709829","volume":"11","author":"X Li","year":"2021","unstructured":"Li, X. et al. Genetic variants of CLPP and M1AP are associated with risk of Non-Small cell lung cancer. Front. Oncol. 11, 709829. https:\/\/doi.org\/10.3389\/fonc.2021.709829 (2021).","journal-title":"Front. Oncol."},{"issue":"2","key":"18211_CR50","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41389-021-00306-1","volume":"10","author":"YG Lee","year":"2021","unstructured":"Lee, Y. G. et al. LONP1 and CLPP cooperatively regulate mitochondrial proteostasis for cancer cell survival. Oncogenesis 10 (2), 18. https:\/\/doi.org\/10.1038\/s41389-021-00306-1 (2021).","journal-title":"Oncogenesis"},{"issue":"13","key":"18211_CR51","doi-asserted-by":"publisher","first-page":"e149906","DOI":"10.1172\/JCI149906","volume":"132","author":"R Kumar","year":"2022","unstructured":"Kumar, R. et al. A mitochondrial unfolded protein response inhibitor suppresses prostate cancer growth in mice via HSP60. J. Clin. Invest. 132 (13), e149906. https:\/\/doi.org\/10.1172\/JCI149906 (2022).","journal-title":"J. Clin. Invest."},{"issue":"4","key":"18211_CR52","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/bju.15229","volume":"127","author":"CM Devlin","year":"2021","unstructured":"Devlin, C. M., Simms, M. S. & Maitland, N. J. Benign prostatic hyperplasia\u2014what do we know? BJU Int. 127 (4), 389\u2013399. https:\/\/doi.org\/10.1111\/bju.15229 (2021).","journal-title":"BJU Int."},{"issue":"9","key":"18211_CR53","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.7150\/ijbs.84994","volume":"19","author":"W Chen","year":"2023","unstructured":"Chen, W. et al. The potential role and mechanism of circrna\/mirna axis in cholesterol synthesis. Int. J. Biol. Sci. 19 (9), 2879\u20132896. https:\/\/doi.org\/10.7150\/ijbs.84994 (2023).","journal-title":"Int. J. Biol. Sci."},{"issue":"1","key":"18211_CR54","doi-asserted-by":"publisher","first-page":"e1003988","DOI":"10.1371\/journal.pmed.1003988","volume":"20","author":"S Fang","year":"2023","unstructured":"Fang, S. et al. Association between genetically proxied PCSK9 Inhibition and prostate cancer risk: a Mendelian randomisation study. PLoS Med. 20 (1), e1003988. https:\/\/doi.org\/10.1371\/journal.pmed.1003988 (2023).","journal-title":"PLoS Med."},{"issue":"11","key":"18211_CR55","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.3390\/life12111769","volume":"12","author":"P Basavaraj","year":"2022","unstructured":"Basavaraj, P. et al. Alpinumisoflavone exhibits the therapeutic effect on prostate cancer cells by repressing AR and Co-Targeting FASN- and HMGCR-Mediated lipid and cholesterol biosynthesis. Life (Basel). 12 (11), 1769. https:\/\/doi.org\/10.3390\/life12111769 (2022).","journal-title":"Life (Basel)"},{"key":"18211_CR56","doi-asserted-by":"publisher","first-page":"102483","DOI":"10.1016\/j.fsigen.2021.102483","volume":"52","author":"J Liu","year":"2021","unstructured":"Liu, J. et al. Identification of coding region SNPs from specific and sensitive mRNA biomarkers for the Deconvolution of the semen donor in a body fluid mixture. Forensic Sci. Int. Genet. 52, 102483. https:\/\/doi.org\/10.1016\/j.fsigen.2021.102483 (2021).","journal-title":"Forensic Sci. Int. Genet."},{"issue":"10","key":"18211_CR57","doi-asserted-by":"publisher","first-page":"e164954","DOI":"10.1172\/jci.insight.164954","volume":"8","author":"Y Zhu","year":"2023","unstructured":"Zhu, Y. et al. Sorbitol reduction via govorestat ameliorates synaptic dysfunction and neurodegeneration in sorbitol dehydrogenase deficiency. JCI Insight. 8 (10), e164954. https:\/\/doi.org\/10.1172\/jci.insight.164954 (2023).","journal-title":"JCI Insight"},{"issue":"5","key":"18211_CR58","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41588-020-0615-4","volume":"52","author":"A Cortese","year":"2020","unstructured":"Cortese, A. et al. Biallelic mutations in SORD cause a common and potentially treatable hereditary neuropathy with implications for diabetes. Nat. Genet. 52 (5), 473\u2013481. https:\/\/doi.org\/10.1038\/s41588-020-0615-4 (2020).","journal-title":"Nat. Genet."},{"issue":"7","key":"18211_CR59","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1111\/ene.15793","volume":"30","author":"N Pons","year":"2023","unstructured":"Pons, N. et al. SORD-related peripheral neuropathy in a French and Swiss cohort: clinical features, genetic analyses, and sorbitol dosages. Eur. J. Neurol. 30 (7), 2001\u20132011. https:\/\/doi.org\/10.1111\/ene.15793 (2023).","journal-title":"Eur. J. Neurol."},{"issue":"2","key":"18211_CR60","doi-asserted-by":"publisher","first-page":"910","DOI":"10.3390\/ijms24020910","volume":"24","author":"F Lasorsa","year":"2023","unstructured":"Lasorsa, F. et al. Emerging hallmarks of metabolic reprogramming in prostate cancer. Int. J. Mol. Sci. 24 (2), 910. https:\/\/doi.org\/10.3390\/ijms24020910 (2023).","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"18211_CR61","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.21037\/tau-24-209","volume":"13","author":"S Li","year":"2024","unstructured":"Li, S. et al. NOSTRIN is involved in benign prostatic hyperplasia via Inhibition of proliferation, oxidative stress, and inflammation in prostate epithelial cells. Transl Androl. Urol. 13 (9), 2055\u20132069. https:\/\/doi.org\/10.21037\/tau-24-209 (2024).","journal-title":"Transl Androl. Urol."},{"issue":"7","key":"18211_CR62","doi-asserted-by":"publisher","first-page":"541","DOI":"10.2174\/1568009622666220321110926","volume":"22","author":"K Zheng","year":"2022","unstructured":"Zheng, K., Chen, S. & Hu, X. Peroxisome Proliferator-activated receptor gamma Coactivator-1 alpha: a Double-edged sword in prostate cancer. Curr. Cancer Drug Targets. 22 (7), 541\u2013559. https:\/\/doi.org\/10.2174\/1568009622666220321110926 (2022).","journal-title":"Curr. Cancer Drug Targets"},{"issue":"5","key":"18211_CR63","doi-asserted-by":"publisher","first-page":"4911","DOI":"10.3390\/ijms24054911","volume":"24","author":"Z Wang","year":"2023","unstructured":"Wang, Z. et al. Simvastatin improves benign prostatic hyperplasia: role of Peroxisome-Proliferator-Activated Receptor-\u03b3 and classic WNT\/\u03b2-Catenin pathway. Int. J. Mol. Sci. 24 (5), 4911. https:\/\/doi.org\/10.3390\/ijms24054911 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"18211_CR64","doi-asserted-by":"publisher","first-page":"e12802","DOI":"10.7717\/peerj.12802","volume":"10","author":"T Zheng","year":"2022","unstructured":"Zheng, T. et al. Functional mechanism of hsa-miR-128-3p in epithelial-mesenchymal transition of pancreatic cancer cells via ZEB1 regulation. PeerJ 10, e12802. https:\/\/doi.org\/10.7717\/peerj.12802 (2022).","journal-title":"PeerJ"},{"issue":"4","key":"18211_CR65","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/pros.24663","volume":"84","author":"KS Lee","year":"2024","unstructured":"Lee, K. S. et al. A prospective, randomized, open-label, parallel trial comparing the efficacy of \u03b1-blocker or 5\u03b1-reductase inhibitor withdrawal to continued combination therapy on the maintenance of lower urinary tract symptoms in men with benign prostatic hyperplasia. Prostate 84 (4), 403\u2013413. https:\/\/doi.org\/10.1002\/pros.24663 (2024).","journal-title":"Prostate"},{"key":"18211_CR66","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.ijbiomac.2022.11.162","volume":"225","author":"L Zhou","year":"2023","unstructured":"Zhou, L. et al. Decoding CeRNA regulatory network and autophagy-related genes in benign prostatic hyperplasia. Int. J. Biol. Macromol. 225, 997\u20131009. https:\/\/doi.org\/10.1016\/j.ijbiomac.2022.11.162 (2023).","journal-title":"Int. J. Biol. Macromol."},{"issue":"1","key":"18211_CR67","doi-asserted-by":"publisher","first-page":"e0296361","DOI":"10.1371\/journal.pone.0296361","volume":"19","author":"SI Mou","year":"2024","unstructured":"Mou, S. I. et al. Comprehensive characterization of coding and non-coding single nucleotide polymorphisms of the myoneurin (MYNN) gene using molecular dynamics simulation and Docking approaches. PLoS One. 19 (1), e0296361. https:\/\/doi.org\/10.1371\/journal.pone.0296361 (2024).","journal-title":"PLoS One"},{"issue":"4","key":"18211_CR68","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1097\/JU.0000000000002183","volume":"206","author":"LB Lerner","year":"2021","unstructured":"Lerner, L. B. et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA GUIDELINE PART I-Initial Work-up and medical management. J. Urol. 206 (4), 806\u2013817. https:\/\/doi.org\/10.1097\/JU.0000000000002183 (2021).","journal-title":"J. Urol."},{"issue":"12","key":"18211_CR69","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.20892\/j.issn.2095-3941.2023.0335","volume":"20","author":"N Chen","year":"2024","unstructured":"Chen, N. et al. Real-world effectiveness and safety of Goserelin 10.8-mg depot in Chinese patients with localized or locally advanced prostate cancer. Cancer Biol. Med. 20 (12), 1047\u20131059. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2023.0335 (2024).","journal-title":"Cancer Biol. Med."},{"issue":"1","key":"18211_CR70","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1186\/s12885-024-12889-0","volume":"24","author":"JAM Weijers","year":"2024","unstructured":"Weijers, J. A. M. et al. A randomized phase II trial on the addition of dutasteride to combined androgen Blockade therapy versus combined androgen Blockade therapy alone in patients with advanced or metastatic salivary duct carcinoma - the DUCT study protocol. BMC Cancer. 24 (1), 1174. https:\/\/doi.org\/10.1186\/s12885-024-12889-0 (2024).","journal-title":"BMC Cancer"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-18211-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-18211-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-18211-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T02:03:02Z","timestamp":1759197782000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-18211-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["18211"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-18211-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6957357\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,25]]},"assertion":[{"value":"23 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"32901"}}